Register for free to
view the full innovation profile.
An alternative to donor blood for transfusion or as a source of autologous blood for patients with rare blood types
About
We are developing a system that is capable of mass manufacturing mature red blood cells either as an alternative to donor blood for transfusion or as a source of autologous blood for patients with rare blood types. The technology has demonstrated proof of principle and is undergoing scale up. Patented, it is available for commercialisation. When contacting us, please quote reference number 5396.